Prosecution Insights
Last updated: November 12, 2026
Application No. 17/777,832

CASPASE 6 INHIBITORS AND USES THEREOF

Non-Final OA §102
Filed
May 18, 2022
Priority
Nov 22, 2019 — provisional 62/939,263 +1 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shangpharma Innovation Inc.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
97%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
775 granted / 1055 resolved
+13.5% vs TC avg
Strong +23% interview lift
Without
With
+23.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
1109
Total Applications
across all art units

Office Action

§102
DETAILED ACTION Claims 4, 5, 12, 13, 16, 17, 20-22, 26, 30-34, and 44 are currently pending in the instant application. Claims 4, 12, 13, 17, and 21 are rejected. Claims 5, 16, and 20 are objected. Claims 22, 26, 30-34 and 44 are withdrawn from consideration as being for non-elected subject matter. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6 April 2026 has been entered. Election/Restrictions Applicant’s election without traverse of Group I and the species: PNG media_image1.png 118 190 media_image1.png Greyscale in the reply filed on 21 May 2025 has been previously acknowledged. According to MPEP 803.02, the examiner has previously determined whether the elected species is allowable. Applicants’ elected species appears allowable. Therefore, the search and examination has been extended to the compounds of claims 5, 16 and 20 which also appear allowable, and further to the compound PNG media_image2.png 106 202 media_image2.png Greyscale which is not allowable. Claims 4, 5, 12, 13, 16, 17, 20 and 21 have been examined to the extent that they are readable on the elected embodiment, the elected species and the above mentioned compound. Response to Amendment and Arguments Applicant's amendment and arguments filed 24 March 2026 have been fully considered and entered into the instant application. As claim 4 is rejected, the objection to claims 16 and 20 for being dependent upon a rejected base claim is maintained. Applicant’s amendment to claim 4 has perfected priority to US Application No. 62/939,263, therefore, the 35 USC 102(a)(2) rejections as being anticipated by Registry No. 2415779-23-4, Registry No. 2415758-96-0, and WO 2022/072741 are overcome. Claim Objections Claims 5, 16, and 20 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 4, 12, 13, 17, and 21 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by WO 2020/243423, filed 29 May 2020, claiming priority to US Application No. 62/928,931, filed 31 October 2019. WO 2020/243423 discloses the compound I-60 on page 72: PNG media_image3.png 178 268 media_image3.png Greyscale Pharmaceutical compositions are disclosed on page 95, which provides conventional carriers on page 96. The compound I-60 corresponds to the formula PNG media_image4.png 182 274 media_image4.png Greyscale , for example, wherein z11 is 0; R1.4 and R1.5 are each hydrogen; L4 is -NR4-; R4 is hydrogen; R5 is PNG media_image5.png 86 112 media_image5.png Greyscale ; R18, R16, and R17 are each hydrogen; L3 is a unsubstituted alkylene; z2 is 1; and R2 is CX23; wherein X2 is -F. In regards to claim 12, the compound I-60 anticipates instant claim 12 as claim 12 does not limit the formula of claim 4 to PNG media_image6.png 122 292 media_image6.png Greyscale , but merely further limits the formula PNG media_image6.png 122 292 media_image6.png Greyscale , however, the formula of claim 12 can still be PNG media_image7.png 174 316 media_image7.png Greyscale . US Application No. 62/928,931 discloses the compound I-75 on page 56: PNG media_image8.png 146 228 media_image8.png Greyscale which provides support for the compound I-60 in WO 2020/243423. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 23 September 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
Jul 11, 2025
Non-Final Rejection mailed — §102
Oct 06, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §102
Mar 24, 2026
Response after Non-Final Action
Apr 06, 2026
Request for Continued Examination
Apr 07, 2026
Response after Non-Final Action
Sep 28, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790333
PIPERIDINYL-METHYL-PURINE AMINE D-TARTARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS
3y 5m to grant Granted Nov 10, 2026
Patent 12773411
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND PLATINUM-BASED ANTICANCER AGENT
6y 3m to grant Granted Oct 27, 2026
Patent 12759994
ISOLATION METHOD FOR LACTIDE RACEMATE
3y 0m to grant Granted Oct 13, 2026
Patent 12759992
COMPOSITIONS AND METHODS FOR INHIBITING IDO1
2y 10m to grant Granted Oct 13, 2026
Patent 12735385
ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS
2y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
97%
With Interview (+23.4%)
High
PTA Risk
Based on 1055 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month